At this year’s EBMT Annual Meeting, Dr. María-Victoria Mateos (Salamanca, Spain) delivered an impactful presentation titled “MRD in Myeloma as Surrogate Marker for Outcomes.”
She shed light on how the recognition of measurable residual disease (MRD) as a regulatory endpoint represents a major step forward in multiple myeloma care—paving the way for precision medicine and personalized treatment strategies.
Dr. Mateos emphasized that with continued collaboration and innovation, MRD assessments are expected to become a routine part of clinical practice. Future MRD-based studies could even lay the foundation for curative approaches in MM.
A crucial insight from Florence: the future of myeloma therapy is evolving—and MRD is leading the way.
A sincere thank you to Dr. Mateos for sharing her expertise and vision with the global hematology community.
